1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1177/1074248419838511" target="_blank" rel="noreferrer noopener">http://doi.org/10.1177/1074248419838511</a>
Pages
422-427
Issue
5
Volume
24
ISSN
1940-4034
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<a href="http://neomed.idm.oclc.org/login?url=http://doi.org/10.1177/1074248419838511" target="_blank" rel="noreferrer noopener">NEOMED Full-text Holding (if available) - Proxy DOI: 10.1177/1074248419838511</a>
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Update Year & Number
June2020SubmittedList
NEOMED College
NEOMED College of Medicine
NEOMED Department
Department of Internal Medicine
Affiliated Hospital
Cleveland Clinic Akron General Hospital
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
SGLT-2 inhibitors and GLP-1 agonists: First-line therapy for diabetes with established cardiovascular disease.
Publisher
An entity responsible for making the resource available
Journal of cardiovascular pharmacology and therapeutics
Date
A point or period of time associated with an event in the lifecycle of the resource
2019
2019-09
Subject
The topic of the resource
Humans; Treatment Outcome; Risk Factors; Biomarkers/blood; diabetes; GLP-1 agonists; SGLT-2 inhibitors; Blood Glucose/drug effects/metabolism; Cardiovascular Diseases/blood/diagnosis/mortality/prevention & control; Diabetes Mellitus Type 2/blood/diagnosis/drug therapy/mortality; Glucagon-Like Peptide-1 Receptor/agonists; Incretins/adverse effects/therapeutic use; Sodium-Glucose Transporter 2 Inhibitors/adverse effects/therapeutic use
Creator
An entity primarily responsible for making the resource
Sajja AP; Dey AK; Guha A; Elnabawi Y; Joshi AA; Kalra A
Description
An account of the resource
There is a growing body of evidence that diabetes represents a significant and largely modifiable risk factor for cardiovascular disease (CVD). It is known to markedly increase the risk of CVD-with CVD accounting for 2 of every 3 deaths in patients with diabetes. It is suggested that once patients with diabetes develop clinical coronary disease, they have a grim prognosis. In 2008, the Food and Drug Association mandated the evidence of CV safety in any new diabetic therapy, leading to a multitude of large CV outcome trials to assess CV risk from these medications. However, several of these outcome trials with novel antidiabetic therapies have demonstrated not only safety but a clear and definite CV advantage in patients with type 2 diabetes. In this review, we discuss 2 relatively newer classes of diabetic drugs, sodium glucose cotransport 2 inhibitors and glucagon-like peptide 1 agonists, evaluate their efficacy in improving CV outcomes, and discuss the future of CV prevention with these agents.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1177/1074248419838511" target="_blank" rel="noreferrer noopener">10.1177/1074248419838511</a>
PMID: 31064213
Rights
Information about rights held in and over the resource
Copyright © 2019 Elsevier Inc. All rights reserved.
Format
The file format, physical medium, or dimensions of the resource
journalArticle
2019
Biomarkers/blood
Blood Glucose/drug effects/metabolism
Cardiovascular Diseases/blood/diagnosis/mortality/prevention & control
Cleveland Clinic Akron General Hospital
Department of Internal Medicine
Dey AK
Diabetes
Diabetes Mellitus Type 2/blood/diagnosis/drug therapy/mortality
Elnabawi Y
GLP-1 agonists
Glucagon-Like Peptide-1 Receptor/agonists
Guha A
Humans
Incretins/adverse effects/therapeutic use
Joshi AA
Journal of cardiovascular pharmacology and therapeutics
journalArticle
June2020SubmittedList
Kalra A
NEOMED College of Medicine
Risk Factors
Sajja AP
SGLT-2 inhibitors
Sodium-Glucose Transporter 2 Inhibitors/adverse effects/therapeutic use
Treatment Outcome